目的 探討寒喘祖帕顆粒聯(lián)合布地奈德福莫特羅粉吸入劑治療支氣管哮喘的臨床療效。方法 選取2016年2月—2017年2月在玉田縣醫(yī)院進(jìn)行治療的哮喘患者113例為研究對(duì)象，所有患者根據(jù)用藥的差別分為對(duì)照組（56例）和治療組（57例）。對(duì)照組吸入布地奈德福莫特羅粉吸入劑，初始2吸/次，癥狀控制后調(diào)整為1吸/次，2次/d。治療組在對(duì)照組基礎(chǔ)上口服寒喘祖帕顆粒，1袋/次，2次/d。兩組患者均治療1個(gè)月。觀察兩組的臨床療效，比較兩組的臨床癥狀消失時(shí)間、C反應(yīng)蛋白（CRP）、炎性因子和肺功能。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為82.14%、96.49%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，治療組咳嗽消失時(shí)間、哮鳴音消失時(shí)間、呼吸困難緩解時(shí)間均顯著短于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，兩組血清CRP、白細(xì)胞介素-6（IL-6）和腫瘤壞死因子-α（TNF-α）水平均顯著降低，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）；且治療組這些觀察指標(biāo)明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，兩組用力呼氣量占用力肺活量比值（FEV1/FVC）、最大呼氣流速（PEF）和用力肺活量（FVC）均顯著升高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P < 0.05）；且治療組這些觀察指標(biāo)明顯高于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。結(jié)論 寒喘祖帕顆粒聯(lián)合布地奈德福莫特羅粉吸入劑治療支氣管哮喘具有較好的臨床療效，能改善肺功能，縮短臨床癥狀消失時(shí)間，調(diào)節(jié)炎性因子水平，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Hanchuan Zupa Granules combined with Budesonide and Formoterol Fumarate Powder for inhalation in treatment of bronchial asthma. Methods Patients (113 cases) with bronchial asthma in Yutian County Hospital from February 2016 to February 2017 were enrolled in this study. According to the difference treatment plan, patients were divided into the control group (56 cases) and the treatment group (57 cases). Patients in the control group were inhalation administered with Budesonide and Formoterol Fumarate Powder for inhalation, initial 2 suctions/time, after symptom control, adjusted to 1 suction/time, once daily. Patients in the treatment group were po administered with Hanchuan Zupa Granules on the basis of the control group, 1 bag/time, once daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacies were evaluated, and the disappearance time of clinical symptoms, the levels of CRP and inflammatory factors, and lung function in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 82.14% and 96.49%, respectively, and there was difference between two groups (P < 0.05). After treatment, coughing disappearance time, wheezing disappearance time, and dyspnea remission time in the treatment group were significantly shorter than those in the control group, and there was difference between two groups (P < 0.05). After treatment, the levels of serum CRP, IL-6, and TNF-α in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, FEV1/FVC, PEF and FVC in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Hanchuan Zupa Granules combined with Budesonide and Formoterol Fumarate Powder for inhalation has clinical curative effect in treatment of bronchial asthma, can improve lung function, shorten disappearance times of clinical symptoms, and regulate inflammatory factors, which has a certain clinical application value.